Research programme: AKR1C3 - Penzymes
Latest Information Update: 25 Jul 2016
At a glance
- Originator University of Pennsylvania
- Developer Penzymes
- Class Aminobenzoic acids; Chlorobenzenes; Indoles; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action AKR1C3 protein inhibitors; Hormone inhibitors; Steroid inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Breast cancer; Endometrial cancer; Prostate cancer